ENZ.N
Latest Trade
3.04USDChange
0.05(+1.67%)Volume
91,937Today's Range
-
3.1352 Week Range
-
4.76As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 2.99 |
|---|---|
Open | 2.96 |
Volume | 91,937 |
3M AVG Volume | 6.52 |
Today's High | 3.13 |
Today's Low | 2.81 |
52 Week High | 4.76 |
52 Week Low | 1.56 |
Shares Out (MIL) | 47.90 |
Market Cap (MIL) | 145.60 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Harbert Discovery Fund Says Sent Letter To Enzo Biochem's Independent Members Of Board
Enzo Biochem Receives FDA Emergency Use Authorization For Testing Pooled Samples On Three Platforms For Detection Of Coronavirus Sars-Cov-2
Enzo Biochem Reviews Position Of Institutional Shareholder Services
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.
Industry
Healthcare Facilities
Executive Leadership
Barry W. Weiner
President, Treasurer
Elazar Rabbani
Chairman of the Board, Chief Executive Officer, Secretary
David A. Bench
Chief Financial Officer, Principal Accounting Officer
Kara Cannon
Chief Commercial Officer
Dieter Schapfel
Chief Medical Director - Enzo Clinical Labs
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 1.72 |
Price To Book (MRQ) | 2.47 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 19.87 |
LT Debt To Equity (MRQ) | 7.83 |
Return on Investment (TTM) | -22.59 |
Return on Equity (TTM) | -17.23 |
* ENZO ANNOUNCES ISSUANCE OF U.S. PATENT FOR METHODS OF TREATING LIVER CANCER USING PROPRIETARY COMPOUND SK1-I
* AT QUARTER-END, CASH, CASH EQUIVALENTS AND RESTRICTED CASH TOTALED $55 MILLION
* ENZO ANNOUNCES ISSUANCE OF U.S. PATENT FOR METHODS OF USING PROPRIETARY COMPOUND SK1-I IN PATIENTS; EXPLORING OPTIONS FOR DEVELOPMENT AS A POTENTIAL TREATMENT FOR COVID-19
* ENZO BIOCHEM INC - ON APRIL 23, GOT ABOUT $7 MILLION FROM CITIBANK N.A., COMPANY S EXISTING LENDER, PURSUANT TO PAYCHECK PROTECTION PROGRAM Source text: [https://bit.ly/357GGZ0] Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* ENZO BIOCHEM LAUNCHES PROPRIETARY COVID-19 DIAGNOSTIC TEST UNDER FDA’S EMERGENCY USE AUTHORIZATION
* ENZO BIOCHEM - IN MARCH, SAW MATERIAL DECLINE IN LABORATORY TESTING VOLUMES DUE TO COVID-19 PANDEMIC AS PATIENTS REDUCED PHYSICIAN OFFICE VISITS
The U.S. Supreme Court on Monday turned away an appeal by Enzo Biochem Inc of a ruling that invalidated some of its medical testing patents, rebuffing the company's arguments that the decision contradicted precedent and contravened the standard of proof for proving patent...
* ENZO BIOCHEM’S FULL SERVICE CLINICAL LABORATORY TO LAUNCH CORONAVIRUS (COVID-19) TESTING SERVICES NEXT WEEK
* AT QUARTER-END, CASH, CASH EQUIVALENT AND RESTRICTED CASH TOTALED $52 MILLION, AND WORKING CAPITAL AMOUNTED TO $48 MILLION Source text for Eikon: Further company coverage:
* HARBERT DISCOVERY FUND - GLASS LEWIS JOINS ISS IN RECOMMENDING SHAREHOLDERS VOTE AGAINST ENZO PROPOSAL TO INCREASE SIZE OF BOARD Source text: (http://bit.ly/2wz7WlT) Further company coverage:
* ISS RECOMMENDS SHAREHOLDERS VOTE AGAINST ENZO PROPOSAL TO INCREASE SIZE OF BOARD Source text for Eikon: Further company coverage:
* ENZO BIOCHEM REPORTS PUBLICATION OF STUDY DETAILING PROMISING ACTIVITY OF DRUG CANDIDATE SK1-I IN A MODEL OF LUPUS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* ENZO BIOCHEM ANNOUNCES SIGNIFICANT MILESTONE WITH APPROVAL OF PROPRIETARY GENFLEX PLATFORM Source text for Eikon: Further company coverage:
* ENZO BIOCHEM - HARBERT DISCOVERY FUND FILED LAWSUIT AGAINST CO, MEMBERS OF BOARD OF DIRECTORS IN U.S. DISTRICT COURT FOR SOUTHERN DISTRICT OF NEW YORK
* ENZO BIOCHEM - U.S. COURT OF APPEALS ISSUED OPINION AFFIRMING LOWER COURT JUDGMENTS OF PATENT INVALIDITY FOR U.S. PATENT NOS. 6,992,180 & 8,097,405
A federal appeals court on Thursday dealt a blow to Enzo Life Sciences Inc, letting stand lower-court decisions that invalidated two of its patents for medical-testing technologies that use modified building blocks of DNA to detect and reveal disease and genetic defects.
* ENZO BIOCHEM INC - CO ALONG WITH ITS UNIT ENTERED INTO A SETTLEMENT AGREEMENT AS OF FEBRUARY 5, 2019 WITH ROCHE - SEC FILING
* ENZO BIOCHEM INC - PATENT TRIAL AND APPEAL BOARD HAS DENIED A PETITION FILED BY HOLOGIC FOR INTER PARTES REVIEW Source text for Eikon: Further company coverage:
* QTRLY LOSS PER SHARE $0.02 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
* GORDON JOSEPH WILL BE ACTING CFO Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.